NewAmsterdam Pharma (NAMS) Share-based Compensation (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Share-based Compensation data on file, last reported at $18.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 18.33% year-over-year to $18.0 million; the trailing twelve-month figure through Mar 2026 stood at $62.2 million (down 2.99% YoY), and the FY2025 full-year result was $59.4 million, up 76.76% from the prior year.
• Share-based Compensation improved to $18.0 million in Q1 2026, from $14.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $32.6 million in Q4 2024 to a low of $989000.0 in Q1 2024.
• A 4-year average of $11.7 million and a median of $8.3 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation tumbled 87.01% in 2024 and jumped 1438.22% in 2025, its largest moves.
• Tracing NAMS's Share-based Compensation over 4 years: stood at $6.0 million in 2023, then jumped by 443.29% to $32.6 million in 2024, then sank by 57.02% to $14.0 million in 2025, then grew by 28.37% to $18.0 million in 2026.
• Business Quant data shows NAMS's Share-based Compensation at $18.0 million in Q1 2026, $14.0 million in Q4 2025, and $15.0 million in Q3 2025.